Compare Amphastar Pharmaceuticals Inc (AMPH) vs MPLX LP (MPLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs MPLX LP — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while MPLX LP trades at $58.43 (market cap $57.79B). The key difference: MPLX LP is far larger — about 70× Amphastar Pharmaceuticals Inc's market cap, and MPLX LP pays a 7.56% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MPLX | |
|---|---|---|
Market Cap | $826.08M | $57.79B |
Sector | Health | Technology |
52-Week High | $30.81 | $59.17 |
52-Week Low | $16.87 | $47.80 |
Enterprise Value | $1.22B | $82.42B |
Dividend Yield | — | 7.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
MPLX trades at $56.95, down 0.42% on the day, with a bullish technical outlook supported by moving averages and key support at $56. The company reported strong profitability with a 41.24% net income margin and a trailing P/E of 12.33. Recent earnings showed beats in Q3 and Q4 2025 but a miss in Q1 2026, with Q2 results pending. A $1.08 dividend for H1-26 underscores its income appeal, while analyst consensus remains strongly positive with a $60.60 price target.
The outlook for MPLX is favorable, driven by stable cash flows from fee-based midstream operations and a high dividend yield. Risks include exposure to energy market volatility and a high debt-to-asset ratio of 90.06%. With 71% of analysts rating it a Buy and solid fundamentals, the stock presents a compelling opportunity for income-focused investors, though macroeconomic headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
